You do realize many companies run several trials for the same indications even if past trials have failed right ?

For example SNPX failed to meet their end point however they did show improvement in a sub population so the NIH granted them money to do a second trial with more specific endpoints.

I have my opinions on Covid that I’ll keep to myself, as far as how much of a market there rly is for us. Regardless it’s clear that we have a place for treatment of Covid. We just need to get past the bureaucracy...

The market isn’t always smart. Look at the people who purchased this at .30. IMO they are the smart ones.